Literatur zum Artikel: Schwarz

• Literatur

• 1 Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
• 2 Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312: 643-646.
• 3 Riechmann L, Clark M, Waldmann H. et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
• 4 Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-308.
• 5 Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988; 240: 1038-1041.
• 6 Toleikis L, Broders O, Dubel S. Cloning singlechain antibody fragments (scFv) from hybridoma cells. Meth Mol Med 2004; 94: 447-458.
• 7 McCafferty J, Griffiths AD, Winter G. et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552-554.
• 8 Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23: 1105-1116.
• 9 Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2: 15-28.
• 10 Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-443.
• 11 Shattil S, Hoxie J, Cunningham M. et al. Changes in the platelet membrane glycoprotein IIb. IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114.
• 12 Bougie DW, Wilker PR, Wuitschick ED. et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100: 2071-2076.
• 13 Dasgupta H, Blankenship JC, Wood GC. et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000; 140: 206-211.
• 14 Peter K, Schwarz M, Ylanne J. et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-3249.
• 15 Peter K, Straub A, Kohler B. et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999; 84: 519-524.
• 16 Schwarz M, Rottgen P, Takada Y. et al. Singlechain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. Faseb J 2004; 18: 1704-1706.
• 17 Kriangkum J, Xu B, Nagata LP. et al. Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 2001; 18: 31-40.
• 18 Hayden MS, Linsley PS, Gayle MA. et al. Singlechain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther Immunol 1994; 1: 3-15.
• 19 Schrör K. Haemostaseology. Internist (Berl) 2005; 46: 873-881.
• 20 Bode C, Meinhardt G, Runge MS. et al. Platelettargeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991; 84: 805-813.
• 21 Hagemeyer CE, Tomic I, Weirich U. et al. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase. J Thromb Haemost 2004; 2: 797-803.
• 22 Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-552.
• 23 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132.
• 24 Bode C, Hanson SR, Schmedtje Jr JF. et al. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. Circulation 1997; 95: 800-804.
• 25 Peter K, Graeber J, Kipriyanov S. et al. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation 2000; 101: 1158-1164.
• 26 Hagemeyer CE, Tomic I, Jaminet P. et al. Fibrintargeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide. Thromb Haemost 2004; 92: 47-53.
• 27 Frelinger 3rd AL, Du XP, Plow EF. et al. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem 1991; 266: 17106-17111.
• 28 Stoll P, Bassler N, Hagemeyer CE. et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007; 27: 1206-1212.
• 29 Ding BS, Gottstein C, Grunow A. et al. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 2005; 106: 4191-4198.
• 30 Ding FX, Yan HL, Lu YM. et al. Cloning, purification and biochemical characterization of a thrombus-ditargeting thrombolytic agent, comprised of annexin B1, ScuPA-32K and fibrin-adherent peptide. J Biotechnol 2006; 126: 394-405.